Lexington, Mass. (PRWEB) August 14, 2013
Imprivata®, a leading global provider of healthcare IT security solutions, today announced that its bookings for the second quarter of 2013 increased by more than 30 percent as compared to bookings in the second quarter of 2012. Helping to drive this growth was the addition of 75 new organizations to Imprivata’s global healthcare client portfolio, which now includes more than 1,000 customers and more than 2.6 million licensed users worldwide. Imprivata also added 48 new employees during the second quarter, increasing its global headcount to more than 250.
“In the second quarter, we continued to grow our global customer portfolio and help healthcare organizations align clinical and IT requirements to solve some of their most critical challenges,” said Omar Hussain, president and CEO of Imprivata. “Our customers trust Imprivata as a strategic partner to deliver solutions that meet these challenges and allow clinicians to quickly and securely access information and communicate with colleagues to better focus on patient care. We look forward to continued strong growth through the remainder of 2013 and beyond.”
Additional highlights from the quarter include:
- Imprivata appointed Dr. John Halamka to its Board of Directors. Dr. Halamka serves as Chief Information Officer of Beth Israel Deaconess Medical Center and is also Chairman of the New England Healthcare Exchange Network (NEHEN), co-Chair of the national HIT Standards Committee and co-Chair of the Massachusetts HIT Advisory Committee. He is also a professor of medicine at Harvard Medical School and a practicing emergency physician.
- Imprivata also appointed Rodger Weismann to its Board of Directors. Weismann, who also serves as Chairman of Imprivata’s Audit Committee, is a member of the Board of Directors at both Reval and Soundbite Communications, and he previously served as senior vice president and Chief Financial Officer at Phase Forward, a publicly traded provider of data management solutions for clinical trials and drug safety that was acquired by Oracle in August 2010.
- Imprivata OneSign® received the highest scores in the single sign-on (SSO) category in the KLAS® 2013 Mid-Term Performance Review: Software & Services report. This continues the company’s momentum from 2012 when KLAS named OneSign the SSO category leader.
- Imprivata initiated a program to enable customers using the Citrix SSO feature to migrate Imprivata OneSign. As Citrix does not plan to continue development of SSO functionality for Windows 8/Server 2012, it is working with Imprivata to provide a solution that meets customers’ ongoing SSO needs.
- During the quarter, Imprivata sponsored a study by the Ponemon Institute released in the second quarter that underscored the need for more modern communication technologies in healthcare. Titled “The Economic & Productivity Impact of IT Security on Healthcare,” the study found that clinicians waste an average of more than 45 minutes each day due to the use of outdated communication technologies, and the total cost to U.S. hospitals exceeds $8.3 billion annually. The majority of healthcare professionals surveyed also believe secure text messaging could cut patient discharge time by about 50 percent.
Imprivata is a leading global provider of healthcare IT solutions that enable fast, secure and more efficient clinical access, communication and collaboration. Independently recognized as an innovator and market leader, Imprivata helps millions of providers worldwide simplify technology to better focus on patient care. For more information, please visit http://www.imprivata.com.